Literature DB >> 16024288

Report of the 16th follow-up survey of primary liver cancer.

Iwao Ikai1, Shigeki Arii, Takafumi Ichida, Kiwamu Okita, Masao Omata, Masamichi Kojiro, Kenichi Takayasu, Yasuni Nakanuma, Masatoshi Makuuchi, Yutaka Matsuyama, Yoshio Yamaoka.   

Abstract

In the 16th nationwide follow-up survey of primary liver cancer, 19,920 patients were newly registered as patients with primary liver cancer at 795 medical institutions in Japan over a period of 2 years (from January 1, 2000 to December 31, 2001). Of these patients, 94.5% had hepatocellular carcinoma (HCC) and 3.6% had intrahepatic cholangiocarcinoma (ICC). In addition, 21,268 follow-up patients were registered, and a valid response rate of 75.6% was obtained in these follow-up patients. In this study, epidemiological and clinicopathological factors, diagnosis and treatment were investigated in patients who were newly registered in the 16th follow-up survey. As additional statistics, the cumulative survival rates of newly registered patients in the 11th to 16th follow-up surveys were calculated for each histological type (HCC, ICC and combined HCC and ICC) by background factor(s) and treatment, respectively. Furthermore, in patients with HCC, the cumulative survival rates were calculated for several types of treatment (hepatectomy, local ablation therapy and transcatheter arterial chemoembolization). It is anticipated that this follow-up survey will contribute to future research and medical practice for primary liver cancer.

Entities:  

Year:  2005        PMID: 16024288     DOI: 10.1016/j.hepres.2005.04.005

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  36 in total

1.  Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Authors:  Yukinori Imai; Taku Chikayama; Manabu Nakazawa; Kazuhiro Watanabe; Satsuki Ando; Yoshie Mizuno; Kiyoko Yoshino; Kayoko Sugawara; Kazuhiro Hamaoka; Kenji Fujimori; Mie Inao; Nobuaki Nakayama; Masashi Oka; Sumiko Nagoshi; Satoshi Mochida
Journal:  J Gastroenterol       Date:  2011-10-06       Impact factor: 7.527

Review 2.  Management of hepatocellular carcinoma in Japan.

Authors:  Kiwamu Okita
Journal:  J Gastroenterol       Date:  2006-02       Impact factor: 7.527

Review 3.  Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.

Authors:  Tatsuya Yamashita
Journal:  Clin Drug Investig       Date:  2012-08-08       Impact factor: 2.859

4.  Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Alessandro Valdegamberi; Fabio Bagante; Francesca Bertuzzo; Simone Conci; Calogero Iacono
Journal:  J Gastrointest Surg       Date:  2013-09-19       Impact factor: 3.452

5.  Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Silvia Pachera; Alessandro Valdegamberi; Paola Nicoli; Alessandro Cappellani; Giulio Malfermoni; Calogero Iacono
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

6.  Epidemiology of hepatocellular carcinoma in Japan.

Authors:  Takeji Umemura; Tetsuya Ichijo; Kaname Yoshizawa; Eiji Tanaka; Kendo Kiyosawa
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  A case of primary small cell carcinoma of the liver that was treated with chemotherapy.

Authors:  Hiroyasu Morikawa; Yuji Nakayama; Takako Maeda; Yuji Nadatani; Sawako Kobayashi; Shuji Iwai; Masaru Enomoto; Akihiro Tamori; Hiroki Sakaguchi; Nobuhide Oshitani; Shinzoh Kudoh; Norifumi Kawada
Journal:  Hepatol Int       Date:  2008-08-22       Impact factor: 6.047

8.  Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma.

Authors:  Winnie Yeo; Pei-Jer Chen; Junji Furuse; Kwang-Hyub Han; Chiun Hsu; Ho-Yeong Lim; Hanlim Moon; Shukui Qin; Ee-Min Yeoh; Sheng-Long Ye
Journal:  BMC Cancer       Date:  2010-11-10       Impact factor: 4.430

9.  A case of hepatocellular carcinoma with skin injury of the upper abdominal wall after transcatheter arterial chemoembolization: a case report.

Authors:  Hiromitsu Kanzaki; Kazuhiro Nouso; Koji Miyahara; Naoko Kajikawa; Sayo Kobayashi; Ichiro Sakakihara; Shota Iwadow; Shuji Uematsu; Ryoichi Okamoto; Kunihiro Shiraga; Motowo Mizuno; Yasuyuki Araki
Journal:  Cases J       Date:  2009-09-01

10.  Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Authors:  Junji Furuse
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.